Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 11;108(4):798–807. doi: 10.1002/cpt.1848

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Bayer AG. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Rifampicin‐dependent induction relationship between midazolam and different progestins and EE. Induction effects on AUC (a), C_max (b) and unbound vs. total AUC (c) and C_max (d)_. The magnitude of the induction effect is classified into three categories: weak induction (W, GMR > 0.5 and ≤ 0.8), moderate induction (M, GMR > 0.2 and ≤ 0.5) and strong induction (S, GMR ≤ 0.2). Gray shaded areas indicate parity of induction effects. AUC, area under the concentration‐time curve extrapolated to infinity; C_max, observed maximum concentration; CI, confidence interval; DNG, dienogest; DRSP, drospirenone; EE, ethinylestradiol; ENG_(unbound), (unbound) etonogestrel (active metabolite of desogestrel); GMR, geometric mean ratio (with RIF/no RIF); LNG_(unbound), (unbound) levonorgestrel; MDZ, midazolam; NET_(unbound), (unbound) norethindrone.